Fig. 2From: Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trialFinal assessment of clinical responses of patients with locally advanced breast cancer to neoadjuvant chemotherapy (FEC regimen vs. PE regimen). FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen, cCR clinical complete response, cPR clinical partial response, cSD clinical stable disease, cPD clinical progressive disease. *P < 0.05Back to article page